SEATTLE CHILDREN’S signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors. The aim of the collaboration is to fast-track clinical implementation with the goal of opening phase I clinical trials within the next two years....
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
